Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 5 Next >
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
Tickers URGN
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
Tickers URGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.